



Neutrophil gelatinase– associated lipocalin as a screening test in prostate cancer

Necati Muşlu¹, Bahadır Ercan², Serin Akbayır³, Şenay Balcı¹, H. Didem Ovla⁴, Murat Bozlu⁵

ABSTRACT

Objective: Prostate specific antigen (PSA) with digital rectal examination is used for diagnosis of prostate cancer (PCa), where definite diagnosis can only be made by prostate biopsy. Recently neutrophil gelatinase-associated lipocalin (NGAL), a lipocalin family member glycoprotein, come into prominence as a cancer biomarker. This study is aimed to test serum NGAL as a diagnostic biomarker for PCa and discriminate PCa from benign prostatic hyperplasia (BPH).

Material and methods: In this prospective study, 90 patients who underwent transrectal ultrasound-guided 12-core prostate biopsy between May 2015 and September 2015, were evaluated. Histopathologically diagnosed 45 PCa and 45 BPH patients were enrolled in this study. Serum NGAL and PSA levels of all participants were measured, then these data were evaluated by statistical programs.

Results: When sensitivity fixed to 80% specificity of NGAL was better than PSA (49%, 31% respectively). Receiver operating characteristic (ROC) curve analysis showed that NGAL alone or its combined use with PSA have better area under curve (AUC) results than PSA alone (0.662, 0.693, and 0.623 respectively).

Conclusion: In conclusion NGAL gave promising results such as increased sensitivity and a better AUC values in order to distinguish PCa from BPH. NGAL showed a potential to be a non-invasive biomarker which may decrease the number of unnecessary biopsies.

Keywords: Biomarker; cancer; hypertrophy; NGAL; prostate; PSA.

This study was presented as a poster at the 27th National Biochemistry Congress in Antalya, on 03–06 November 2015.

¹Department of Biochemistry, Mersin University School of Medicine, Mersin, Turkey

²Department of Biochemistry, Dicle University School of Medicine, Diyarbakır, Turkey

³Karaman State Hospital, Biochemistry Laboratory, Karaman, Turkey

⁴Department of Biostatistics Mersin University School of Medicine, Mersin, Turkey

⁵Department of Urology, Mersin University School of Medicine, Mersin, Turkey

Submitted:
05.10.2016

Accepted:
01.11.2016

Available Online Date:
06.01.2017

Correspondence:
Serin Akbayır
E-mail:
serinakbayir@hotmail.com

©Copyright 2017 by Turkish Association of Urology

Available online at
www.turkishjournalofurology.com

Introduction

Prostate cancer (PCa) is one of the most frequent solid cancer seen among men.^[1,2] Its prevalence increases with increasing average lifespan. Similarly benign prostatic hyperplasia (BPH) is a condition related to aging and consists of prostate tissue enlargement that gives rise to lower urinary tract syndromes. In recent years, with the use of PCa screening tests, PCa can be detected earlier which increases the life quality and decreases rates of mortality caused by PCa. For this purpose annual prostate specific antigen (PSA) screening test is advised to men over the age of 50. Presence of high PSA level together with detection of a suspicious mass during digital rectal examination (DRE), biopsy and histopathological examination is used as the gold standard method for the diagnosis of PCa.^[1-4]

Although there are many biomarkers tested for PCa such as human kallikrein- 2, prostate specific membrane antigen, prostatic acid phos-

phatase, neuroendocrine biomarkers, none of them is a widely used biomarker as PSA.^[5,6] However serum PSA has its own controversies as it reflects malignant character of the prostate as well as the prostate volume. Low specificity of PSA, which is a prostate specific not a cancer specific marker, is the cause of many unnecessary biopsies. Therefore, researchers are still looking for a better biomarker with a higher specificity and sensitivity for PCa.^[5-9]

Recently a lipocalin family member glycoprotein neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2, come into prominence as a cancer biomarker.^[10-12] It is 25-kDa biomarker, and associated with cellular iron absorption, antibacterial activity and epithelial cell differentiation. NGAL was first discovered in neutrophils, and subsequently shown to be expressed in many tissues and cells. There are numerous studies on NGAL which indicate that it could be used as a tool for the diagnosis and monitoring of many diseases.^[10-12] Higher ex-

pression levels and release of NGAL have been shown in acute and chronic inflammatory states as is the case with an acute phase reactant, and also in different cancer types (ovarian, colorectal, breast, esophageal, endometrial and prostate cancers). These studies have argued that NGAL and matrix metalloproteinases (MMP) are involved in extracellular matrix degradation by forming a complex, and NGAL can play an important role in the development, progress, and invasion of cancer.^[13-17]

The aim of this study is to test serum NGAL levels as a biomarker for distinguishing PCa from BPH. To achieve this goal serum NGAL levels with and without serum PSA levels were compared with serum PSA levels alone in terms of their specificity, sensitivity and area under curve (AUC) values.

Material and methods

This prospective study performed on 45 PCa and 45 BPH patients was approved by Ethics Committee of Mersin University Clinical Research Institute. All patients were referred to Urology Clinics with lower urinary tract symptoms (LUTS) and/or elevated serum PSA levels between May 2015 and September 2015. Their medical history including age, tobacco and alcohol consumption, hypertension, diabetes and family history of PCa and BPH were recorded. All participants gave written informed consent at the time of recruitment.

Study population

Patients referred to Urology Clinics with LUTS, and/or for a PCa screening with elevated serum PSA levels were subjected to DRE. The indications for transrectal ultrasound-guided 12-core prostate biopsy were abnormal DRE findings and/or an elevated serum total PSA.

Serum PSA and NGAL analysis

Venous blood of all participants were sampled in standart serum separation tubes and transported to a reference laboratory. After a 10 min centrifugation at 4000 rpm, 500 μ L of serum aliquoted and stored at -80°C for NGAL analysis. PSA levels were measured immediately after sampling via Advia Centaur XP (Siemens Healthcare Diagnostics Inc, Tarrytown, NY, 10591-5097, USA) autoanalyser. NGAL levels were measured with a rapid ELISA kit (KIT 037, BioPorto Diagnostics, Gentofte, Denmark).

Statistical analysis

Continuous measurements were tested for normality using the Kolmogorov-Smirnov and Shapiro-Wilk test. Continuous variables were presented as mean \pm standard deviation (mean \pm SD) and categorical variables were expressed as numbers. Continuous variables were compared across the groups using independent samples t test, and categorical variables with the *chi*-square test. A P value less than 0.05 was considered statistically significant. Diagnostic accuracy of individual biomarkers was mea-

sured by receiver operating characteristic (ROC) curve analysis. AUC, sensitivity and specificity values were calculated. Probabilities were calculated for common effect of biomarkers and evaluated by combined ROC analysis.

Results

Forty-five cases with histopathologically diagnosed PCa and 45 patients with BPH were enrolled in this study. Their demographic data including age, family history, alcohol and tobacco consumption, diabetes mellitus and hypertension were given in Table 1. No difference was observed between groups as for their demographic parameters.

Both serum PSA and NGAL levels were statistically higher ($p=0.044$ for PSA and 0.008 for NGAL) in PCa patients when compared with BPH patients (Table 2). In order to distinguish PCa from BPH, ROC analysis were performed separately for both PSA, NGAL as well as PSA and NGAL in combination (Figure 1). Area under curve (AUC) values for PSA, NGAL and both biomarkers combined were 0.623 ($p=0.0369$), 0.662 ($p=0.0046$) and 0.693 ($p=0.0005$), respectively (Table 3).

When sensitivity levels were fixed to 80% for both tests to see which test has a better specificity to distinguish PCa from BPH, it can easily be seen that NGAL has a better specificity than PSA (49 and 31 %, respectively) (Table 4).

When the sensitivities of PSA, NGAL and their combination were fixed to 64%, specificities rose up to 46%, 62% and 66%, respectively with the cut-off levels shown in Table 5. ROC analysis of both PSA, and NGAL in combination had a better efficiency than both PSA and NGAL alone to distinguish PCa from BPH (Table 5).

Discussion

There is a need for statistically powerful PCa screening tests as in all other cancer types to diagnose the cancer in early stages and to differentiate it from BPH with an increasing incidence rates within 50-60 years. Typical diagnostic procedure starts with the detection of an increased serum PSA level and a positive DRE and ends up with prostate biopsy. In clinical use PSA is the most important biomarker for PCa. In order to overcome the weakness of the test, particularly its low specificity and sensitivity, age specific PSA levels, PSA increasing rate, PSA density and serum PSA derivatives (free and bound form) were performed but none of them was accepted as a routine laboratory test.^[18-22]

When PCa patients compared with healthy people, sensitivity and specificity values of serum PSA levels are about 75% and 55%, respectively. Many of the patients subjected to a biopsy procedure after a screening test received BPH rather than a PCa

Table 1. Demographic variables of the study population

		BPH (n=45)	PCa (n=45)	p
Age (mean±SD) yrs		64.60±9.02	61.98±8.39	0.164
Family history	+	16	9	0.069
	-	29	36	
Alcohol consumption	+	8	6	0.606
	-	37	39	
Tobacco consumption	+	14	6	0.134
	-	31	39	
Diabetes mellitus	+	9	7	0.821
	-	36	38	
Hypertension	+	27	15	0.662
	-	18	30	

BPH: benign prostatic hyperplasia; PCa: prostate cancer; SD: standard deviation

Table 2. Serum PSA and NGAL levels in BPH and PCa patients

	BPH Median (range)	PCa Median (range)	p
PSA (ng/mL)	6.66 (2.39-18.69)	7.75 (3.15-59.47)	0.044
NGAL (pg/mL)	57.1 (23.0-225.7)	78.1 (28.0-197.3)	0.008

BPH: benign prostatic hyperplasia; PCa: prostate cancer; PSA: prostate specific antigen; NGAL: neutrophil gelatinase-associated lipocalin

Table 3. Area under curve with respective 95% confidence intervals and p values of PSA, NGAL, and their combination

	AUC (95% CI)	p
PSA	0.623 (0.52-0.72)	0.0369
NGAL	0.662 (0.56-0.76)	0.0046
PSA + NGAL	0.693 (0.59-0.79)	0.0005

AUC: area under curve; PSA: prostate specific antigen; NGAL: neutrophil gelatinase-associated lipocalin




Figure 1. Receiver operating characteristic curves of serum total PSA, NGAL and PSA and NGAL combination

diagnosis and people were faced complications and costs of unnecessary biopsies.^[23,24]

As in this study when PSA levels are used to distinguish PCa from BPH at a fixed sensitivity level of 80%, specificity of PSA decreases down to 30 percent. Actually PSA levels with a cut-off value of 4 ng/mL is generally used for biopsy decision rather than a cancer marker. Diagnostic power of PSA is reasonable

for distinguishing cancer patients from healthy people but it is insufficient to discriminate between BPH, and PCa. For this reason, there is a need for a biomarker with a higher specificity and sensitivity that will help to reduce the number of unnecessary biopsies and enable early diagnosis of PCa.

Neutrophil gelatinase-associated lipocalin which is a member of lipocalin family is involved in many events such as immune

Table 4. Specificity values of PSA and NGAL when the sensitivity set to 80% with the relevant cut-off values

Cut-off	Sensitivity (%)	Specificity (%)
PSA >5.1 ng/mL	80	31
NGAL >52.9 pg/mL	80	49

PSA: prostate specific antigen; NGAL: neutrophil gelatinase-associated lipocalin

Table 5. Specificities of PSA, NGAL alone and combined tests when sensitivity set to 64% with the relevant cut-off levels

Cut-off	Sensitivity (%)	Specificity (%)
PSA >6.21 ng/mL	64	46
NGAL >63.1 pg/mL	64	62
PSA >4.94 ng/mL NGAL >84.8 pg/mL	64	66

PSA: prostate specific antigen; NGAL: neutrophil gelatinase-associated lipocalin

response, iron transport, cellular growth and regulation of metabolism.^[10,11] It has a role in apoptosis, carcinogenesis, growth and differentiation of normal and neoplastic tissues, invasion and metastasis of cancer cells. Increased serum NGAL concentrations have been accepted as a prognosis- related independent variable in different types of cancer.^[13,16,17,25-28]

Although there are studies showing that increased serum NGAL levels indicate a relation with PCa diagnosis and poor prognosis, there is no study investigating possible role of NGAL in discrimination between benign, and malign diseases of the prostate.^[29-31] In this study, potential role of NGAL in minimizing unnecessary biopsies as a biomarker was investigated and NGAL levels were found to be significant higher than PSA in PCa patients relative to BPH patients.

Receiver operating characteristic curve analysis is a good tool to manifest the characteristics of a biomarker.^[32] In our study when we compared AUC values of PSA and NGAL both separately or in combination, we observed that AUCs of NGAL alone and NGAL-PSA combination have statistically significant higher values than those of PSA alone.

When determining a cut-off value for ROC curve analysis data that represents a better trade off between sensitivity and specificity, at a fixed and high sensitivity level, selecting the screening test with higher specificity is the main strategy for achieving

improved outcomes. Using this strategy, at a similar and higher sensitivity value we set for both NGAL and PSA, we observed that despite NGAL and PSA demonstrated lower specificities, NGAL had a much better specificity than PSA (49, and 31%, respectively). The importance of this finding is that NGAL is a tissue non-specific marker which is known to be under influence of many benign conditions, and had a better specificity than a tissue specific marker, PSA. This result also gives rise to thought a cancer specific marker.^[33,34]

In combined PSA and NGAL analysis, when a cut-off value with high sensitivity for PSA and a cut-off value with high specificity for NGAL were set, we observed that this combination discriminated PCa from BPH more efficiently. However more studies are needed to define more accurate cut-off values for both NGAL alone and PSA-NGAL combination.

Our results suggest that as a screening test serum NGAL concentrations have better specificity than serum PSA levels when discriminating PCa from BPH in patients with abnormal DRE findings. Although NGAL showed a potential to be a non-invasive biomarker which may decrease the number of unnecessary biopsies, more accurate results can be achieved by increasing the number of cases.

Ethics Committee Approval: Ethics committee approval was received for this study from the ethics committee of Mersin University School of Medicine (2015/154).

Informed Consent: Written informed consent was obtained from all participants who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - N.M., B.E., S.A.; Design - N.M., S.A., M.B.; Supervision - B.E., M.B.; Resources - N.M., S.A.; Materials - N.M., S.A., M.B.; Data Collection and/or Processing - Ş.B., B.E., D.O.; Analysis and/or Interpretation - N.M., B.E., H.D.O.; Literature Search - N.M., S.A., B.E., Ş.B.; Writing Manuscript - N.M., B.E.; Critical Review - M.B.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer Clin* 2016;66:7-30. [CrossRef]

2. Aydin S, Boz MY. Rapid changes in the incidence of urinary cancers in Turkey. *Turk J Urol* 2015;41:215-20. [\[CrossRef\]](#)
3. US preventive Services Task Force. Screening for prostate cancer: recommendations and rationale. *An Intern Med* 2002;137:915-6. [\[CrossRef\]](#)
4. Bergstralh EJ, Roberts RO, Farmer SA, Slezak JM, Lieber MM, Jacobsen SJ. Population-based case-control study of PSA and DRE screening on prostate cancer mortality. *Urology* 2007;70:936-41. [\[CrossRef\]](#)
5. Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, et al. Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. *World J Urol* 2011;29:11-4. [\[CrossRef\]](#)
6. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG. Are multiple markers the future of prostate cancer diagnostics? *Clin Biochem* 2004;37:519-28. [\[CrossRef\]](#)
7. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. *J Urol* 1995;154:407-13. [\[CrossRef\]](#)
8. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein. *Cancer Res* 1997;57:3111-4.
9. Catalona WJ, Beiser JA, Smith DS. Serum free PSA and PSA density measurement for predicting cancer in men with prior negative prostatic biopsies. *J Urol* 1997;158:2162-7. [\[CrossRef\]](#)
10. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. *Biochim Biophys Acta* 2000;1482:9-24. [\[CrossRef\]](#)
11. Abella V, Scotece M, Conde J, Gómez R, Lois A, Pino J, et al. The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. *Biomarkers* 2015;20:565-71. [\[CrossRef\]](#)
12. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. *Biochim Biophys Acta* 2012;1826:129-69. [\[CrossRef\]](#)
13. Marchewka Z, Tacik A, Piwowar A. KIM-1 and NGAL as potential biomarkers for the diagnosis and cancer progression. *Postepy Hig Med Dosw* 2016;70:329-36. [\[CrossRef\]](#)
14. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. *Uropean J Cancer* 2007;43:1869-76. [\[CrossRef\]](#)
15. Ricci S, Bruzzese D, Di Carlo A. Evaluation of MMP-2, MMP-9, TIMP1, TIMP2, NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer. *Oncology Lett* 2015;10:2527-32.
16. Lippi G, Meschi T, Nouvenne A, Mattiuzzi C, Borghi L. Neutrophil gelatinase-associated lipocalin in cancer. *Adv Clin Chem* 2014;64:179-219. [\[CrossRef\]](#)
17. Martí J, Fuster J, Solà AM, Hotter G, Molina R, Pelegrina A, et al. Prognostic value of serum neutrophil gelatinase-associated lipocalin in metastatic and nonmetastatic colorectal cancer. *World J Surg* 2013;37:1103-9. [\[CrossRef\]](#)
18. Carter HB, Ferruci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al. Detection of life-threatening prostate cancer with prostate specific antigen velocity during a window of curability. *J Natl Cancer Inst* 2006;98:1521-7. [\[CrossRef\]](#)
19. Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R. Complexed PSA reduces unnecessary prostate biopsies in the 2,6-4 ng/mL range of total PSA. *BJU Int* 2004;94:47-50. [\[CrossRef\]](#)
20. Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I. A prospective study to evaluate the role of complexed prostate specific antigen ratio for the diagnosis of prostate cancer. *J Urol* 2001;165:1549-53. [\[CrossRef\]](#)
21. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. CPSA, CPSAD of total and transitional zone, C/T PSA ratio, f/t PSA ratio, density of total and transition zone PSA: Results of the prospective multicenter European trial. *Urology* 2002;60:4-9. [\[CrossRef\]](#)
22. Mazzucchelli R, Colanzi P, Pomante R, Muzzonigro G, Montironi R. Prostate tissue and serum markers. *Adv Clin Path* 2000;4:111-20.
23. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320-8. [\[CrossRef\]](#)
24. European Association of Urology: Guidelines on prostate cancer. <http://www.erspc.org/psa-screening-cuts-deaths-20-says-worlds-largest-prostate-cancer-study/>.
25. Cho H, Kim JH. Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. *J Histochem Cytochem* 2009;57:513-21. [\[CrossRef\]](#)
26. Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, et al. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. *BMC Cancer* 2012;12:169. [\[CrossRef\]](#)
27. Volpe V, Raia Z, Sanguigno L, Somma D, Mastrovito P, Moscato F, et al. NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells. *J Endocrinol Metab* 2013;98:228-35. [\[CrossRef\]](#)
28. Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. *J Cell Physiol* 2011;226:309-14. [\[CrossRef\]](#)
29. Tung MC, Hsieh SC, Yang SF, Cheng CW, Tsai RT, Wang SC, et al. Knockdown of Lipocalin-2 Suppresses the Growth and Invasion of Prostate Cancer Cells. *Prostate* 2013;73:1281-90. [\[CrossRef\]](#)
30. Mahadevan NR, Rodvold J, Almanza G, Pérez AF, Wheeler MC, Zanetti M. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. *BMC Cancer* 2011;11:229. [\[CrossRef\]](#)

31. Chappell WH, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, et al. Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. *Adv Biol Regul* 2016;60:64-87. [\[CrossRef\]](#)
32. Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. *J Natl Cancer Inst* 2003;95:511-5. [\[CrossRef\]](#)
33. Holmström B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. *BMJ* 2009;339:b3537. [\[CrossRef\]](#)
34. Agnihotri S, Mittal RD, Kapur R, Mandhani A. Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy. *Indian J Med Res* 2014;139:85-6.